Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03706612
Other study ID # R01DK111698
Secondary ID
Status Completed
Phase
First received
Last updated
Start date April 1, 2017
Est. completion date January 4, 2023

Study information

Verified date January 2023
Source University of Hawaii
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Identify the unique associations of body shape to body composition and bone density indices in a pediatric population that represents the variance of sex, age, BMI-Z, and ethnicity found in the US population. Describe the precision and accuracy of optical scans to monitor change in body composition, bone density and metabolic health interventions. Estimate the level of association of optical to common health indicators including metabolic risk factors (glucose, triglycerides, HDL-cholesterol, blood pressure, VAT, WC and strength) by gender, race, age, and BMI-Z. Investigate holistic, high-resolution descriptors of 3D body shape as direct predictors of body composition and metabolic risk using statistical shape models and Latent Class Analysis.


Recruitment information / eligibility

Status Completed
Enrollment 430
Est. completion date January 4, 2023
Est. primary completion date January 4, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 5 Years to 17 Years
Eligibility Inclusion Criteria: - Healthy participants will be included in the study if they have a self-reported ability to: - walk one-quarter of a mile and climb 10 steps without difficulty, - perform activities of daily living (ADLs) without difficulty, and - have no life-threatening conditions or diseases that would alter body composition from what is typical for age, sex, ethnicity, and BMI. Exclusion Criteria: - any internal metal artifact (e.g. pacemakers, internal fixation, arthroplasty), amputation, physical impairment or previous fracture that would alter body composition assessment - Pregnant or breastfeeding. (All premenopausal females will be asked for a spot urine sample for pregnancy test prior to participation. Those unwilling to comply with this will not be included.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
United States Pennington Biomedical Research Center Baton Rouge Louisiana
United States University of Hawaii Cancer Center Honolulu Hawaii
United States University of California, San Francisco San Francisco California

Sponsors (3)

Lead Sponsor Collaborator
University of Hawaii Pennington Biomedical Research Center, University of California, San Francisco

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Fat mass by DXA Measure fat mass and percent fat (arms, legs, trunk, and total) using Dual energy X-ray absorptiometry (DXA) data 1 day
Primary Lean mass by DXA Measure lean mass (arms, legs, trunk, and total) using Dual energy X-ray absorptiometry (DXA) data 1 day
Primary Bone mass by DXA Measure bone mass (arms, legs, lumbar spine, and total) and Bone Mineral Density (spine and total) using Dual energy X-ray absorptiometry (DXA) data 1 day
Primary Fat mass by MRI Measure fat mass and percent fat (arms, legs, trunk, visceral, and total) using MRI data 1 day
Primary Lean mass by MRI Measure lean mass (arms, legs, trunk, and total) using MRI data 1 day
Primary Waist to Hip ratio (WHR) from manual tape measurement Manual physical anthropometry of waist and hip circumferences 1 day
Primary Automatic 3D optical (3DO) scan measurement Automated 3DO measurement generated across the body 1 day
Primary Hand-grip strength Measured by using a hand-grip dynamometer (JAMAR) as a measure of strength and physical capacity. 1 day
Primary Isokinetic peak torque Measure the peak torque value (FT-LBS) generated during isokinetic knee extension/flexion movement evaluation at 60 degrees will be assessed with the HUMAC NORM device 1 day
Primary Isometric peak torque Measure the peak torque value (FT-LBS) generated during isometric knee extension/flexion movement evaluation at 60 degrees will be assessed with the HUMAC NORM device 1 day
Primary Fasting glucose levels Measure fasting glucose levels 1 day
Primary Fasting HbA1c levels Measure fasting HbA1c levels 1 day
Primary Fasting insulin levels Measure fasting insulin levels 1 day
Primary Fasting cholesterol levels Measure fasting cholesterol levels 1 day
Primary Fasting triglycerides levels Measure fasting triglycerides levels 1 day
Secondary Fat loss Measure changes in fat mass during intervention using DXA data. 24 weeks
Secondary Changes in lean mass Measure changes in lean mass (arms, legs, trunk, and total) during intervention using DXA data. 24 weeks
Secondary Changes in WHR Measure changes in WHR during intervention 24 weeks
Secondary Changes in automatic 3DO scan measurement Changes of automated 3DO measurements during intervention 24 weeks
Secondary Changes in isokinetic peak torque Measure the change in peak torque value generated during isokinetic knee extension/flexion movement evaluation at 60 degrees will be assessed with the HUMAC NORM device pre and post intervention. 24 weeks
Secondary Changes in isometric peak torque Measure the change in peak torque value generated during isometric knee extension/flexion movement evaluation at 60 degrees will be assessed with the HUMAC NORM device pre and post intervention 24 weeks
Secondary Total Body Water Measure total body water (L) provided by bioelectrical impedance analysis 24 weeks
Secondary Phase angle Phase angle [PhA(°) = (reactance/electrical resistance) × (180°/?)] will be measured in degrees using bioelectrical impedance analysis. 24 weeks
Secondary Percent body fat Measure percent body fat provided by bioelectrical impedance analysis. 24 weeks
Secondary Body circumference from 2D imaging A conventional digital camera will be used to capture 2D images of participants in a standardized pose. Body circumference will be estimated using these images. 24 weeks
Secondary Systolic and Diastolic blood pressure levels will be assessed Manually measure systolic and diastolic blood pressure levels. 24 weeks
Secondary Diet History Questionnaire II The Diet History Questionnaire II estimates the participants nutrition intake by asking the participant a series of questions 24 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT06052553 - A Study of TopSpin360 Training Device N/A
Completed NCT05511077 - Biomarkers of Oat Product Intake: The BiOAT Marker Study N/A
Recruiting NCT04632485 - Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
Completed NCT05931237 - Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults N/A
Completed NCT04527718 - Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers Phase 1
Terminated NCT04556032 - Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women N/A
Completed NCT04107441 - AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects Phase 1
Completed NCT04065295 - A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225 Phase 1
Completed NCT04998695 - Health Effects of Consuming Olive Pomace Oil N/A
Completed NCT01442831 - Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects Phase 1
Terminated NCT05934942 - A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood Phase 1
Recruiting NCT05525845 - Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI N/A
Completed NCT05515328 - A Study in Healthy Men to Test How BI 685509 is Processed in the Body Phase 1
Completed NCT04967157 - Cognitive Effects of Citicoline on Attention in Healthy Men and Women N/A
Completed NCT05030857 - Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects Phase 1
Recruiting NCT04714294 - Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers Phase 1
Recruiting NCT04494269 - A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls Phase 1
Completed NCT04539756 - Writing Activities and Emotions N/A
Recruiting NCT04098510 - Concentration of MitoQ in Human Skeletal Muscle N/A
Completed NCT03308110 - Bioavailability and Food Effect Study of Two Formulations of PF-06650833 Phase 1